Chong Kun Dang Pharm Research Institute

Chong Kun Dang (CKD) is a leading South Korean pharmaceutical company founded in 1941, specializing in the development of innovative small molecules, biologics, and biosimilars. The company's Research Institute focuses on high-potential therapeutic areas including oncology, neurology, and immunology, with a notable emphasis on its proprietary Histone Deacetylase 6 (HDAC6) inhibitor platform. Key pipeline assets include CKD-510 for rare neurological diseases and CKD-702, a bispecific antibody targeting EGFR and c-Met for lung cancer. CKD has successfully commercialized several products, including the biosimilar Nesbell, and maintains a robust global presence through strategic partnerships and licensing agreements. In 2023, the company secured a landmark $1.3 billion licensing deal with Novartis for its lead HDAC6 candidate.